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Opposing roles of NF-kB in anti-cancer
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In malignancies, enhanced nuclear factor-kB (NF-kB) activity is largely viewed as an oncogenic property that also
confers resistance to chemotherapy. Recently, NF-kB has been postulated to participate in a senescence-associated
and possibly senescence-reinforcing cytokine response, thereby suggesting a tumor-restraining role for NF-kB.
Using a mouse lymphoma model and analyzing transcriptome and clinical data from lymphoma patients, we show
here that therapy-induced senescence presents with and depends on active NF-kB signaling, whereas NF-kB
simultaneously promotes resistance to apoptosis. Further characterization and genetic engineering of primary
mouse lymphomas according to distinct NF-kB-related oncogenic networks reminiscent of diffuse large B-cell
lymphoma (DLBCL) subtypes guided us to identify Bcl2-overexpressing germinal center B-cell-like (GCB) DLBCL
as a clinically relevant subgroup with significantly superior outcome when NF-kB is hyperactive. Our data
illustrate the power of cross-species investigations to functionally test genetic mechanisms in transgenic mouse
tumors that recapitulate distinct features of the corresponding human entity, and to ultimately use the mouse
model-derived genetic information to redefine novel, clinically relevant patient subcohorts.
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Initially identified by their interaction with immuno-
globulin enhancer sequences, nuclear factor-kB (NF-kB)
transcription factors control the expression of a large set
of target genes, thereby orchestrating a plethora of bi-
ological functions, including cell survival, inflammation,
and immunity (Sen and Baltimore 1986; Hayden and
Ghosh 2008). Specifically, cancer-relevant properties such
as suppression of apoptosis, growth promotion, enhanced
migration, and invasiveness have been attributed toNF-kB
signaling (Ben-Neriah and Karin 2011). Activating muta-
tions in NF-kB transcription factors or their upstream
signaling components are common findings in various
lymphoma entities (Lenz et al. 2008a; Compagno et al.
2009; for review, see also Staudt 2010 and references
therein). Although oncogenic mutations in NF-kB signal
mediators appear to be rare in solid tumors, oncogenic
signaling may enhance NF-kB activity in the absence
of mutations, as inflammation-associated NF-kB-driven
cytokine production promotes carcinogenesis in a non-
cell-autonomous fashion (Staudt 2010; Ben-Neriah and
Karin 2011). Accordingly, mouse models demonstrated
an oncogenic role for NF-kB in the development of
lymphomas and solid tumors (Basseres et al. 2010;
Calado et al. 2010; Yang et al. 2010). However, other
mouse model-based studies found NF-kB transcription
factors or upstream activators rather to act as tumor
suppressors (Luedde et al. 2007; Keller et al. 2010),
thereby underscoring the complexity and potential con-
text dependency of NF-kB network-mediated effector
functions (Perkins and Gilmore 2006). Indeed, NF-kB has
been shown tomediate or, conversely, block apoptosis in
different settings (Wang et al. 1998; Ryan et al. 2000),
and non-cell-autonomous components of NF-kB action
may further add to the diverse roles NF-kB apparently
plays in tumor development.
Activation of NF-kB also occurs in response to DNA
damage (Brach et al. 1991; Stilmann et al. 2009; Hinz et al.
2010), the mode by which most conventional chemother-
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apeutic agents exert their anti-cancer activity. Enhanced
anti-tumor efficacy has been observed following inhibi-
tion of NF-kB function and was primarily linked to NF-
kB-mediated suppression of apoptosis as the chemoresist-
ance-underlyingmechanism (Wang et al. 1999). Given the
complexity of NF-kB-governed biological responses, their
double-edged impact on tumor development, and the
inducibility of many of these responses by both onco-
genes and chemotherapeutic agents, NF-kB effector func-
tions other than anti-apoptosis are likely to contribute to
impaired treatment efficacy (Li and Sethi 2010), while, in
turn, not all drug-related NF-kB-controlled functions may
compromise chemosensitivity.
Complementing apoptosis as a stress-inducible fail-safe
mechanism, premature cellular senescence is a terminal
cell cycle arrest program acutely initiated via DNA
damage response (DDR) signaling evoked by oncogenic
activation or anti-cancer chemotherapy (Schmitt 2007;
Kuilman et al. 2010). While oncogene-induced senescence
(OIS), most thoroughly studied in response to Ras/Raf-type
oncogenes, imposes an anti-tumor barrier in early, (pre)-
malignant lesions (Serrano et al. 1997; Braig et al. 2005),
therapy-induced senescence (TIS) has been shown to im-
prove the long-term outcome of cancer therapy (Schmitt
et al. 2002). Importantly, both OIS and TIS exhibit a senes-
cence-associated secretory phenotype (SASP) (Coppe et al.
2008), an array of predominantly proinflammatory cyto-
kines whose autocrine or paracrine action reportedly re-
inforces the senescent arrest at least in some settings and
whose cross-talk to the innate host immune systemmight
explain the immune-mediated clearance of senescent tu-
mor cells (Xue et al. 2007; Acosta et al. 2008; Kuilman
et al. 2008). Many of the SASP factors are bona fide
NF-kB targets with NF-kB-binding sites in their pro-
moters (Feuerhake et al. 2005; Acosta et al. 2008; Kuilman
et al. 2008), rendering them responsive toNF-kB activation,
as shown for poly(ADP-ribose)-polymerase-1 (PARP-1)-
mediated genotoxic therapies or induction of oncogenic
Ras (Finco et al. 1997; Stilmann et al. 2009; Ohanna et al.
2011). Silencing of NF-kB transcription factors in senes-
cent human fibroblasts enhanced their proliferative ca-
pacity, suggesting that NF-kB signaling may indeed con-
tribute to the senescent growth arrest (Rovillain et al.
2011).
In this study, we used primary Em-myc transgenicmouse
lymphomas, a well-established model for human aggres-
sive B-cell non-Hodgkin’s lymphomas (B-NHL), and in-
formation from human diffuse large B-cell lymphomas
(DLBCL, the most common type of aggressive B-NHL) in
a cross-species approach to identify oncogenic networks in
which chemotherapy-activated NF-kB signaling no longer
mediates resistance but promotes cellular senescence and
contributes to the outcome of anti-cancer treatment.
Results
NF-kB activity is increased in TIS
We previously established the lymphoma-prone Em-myc
transgenic mouse as a model system for TIS (Schmitt
et al. 2002; Reimann et al. 2007). Primary Myc-driven
B-cell lymphomas (hereafter referred to as ‘‘control’’
lymphomas) were isolated, underwent retroviral bcl2 trans-
duction to block apoptosis, and were exposed to the DNA-
damaging chemotherapeutic agent adriamycin (ADR). At
day 5, ADR-treated control;bcl2 lymphomas were fully
growth-arrested, stained negative for the proliferation
marker Ki67, and uniformly exhibited senescence-associ-
ated b-galactosidase activity (SA-b-gal) (Supplemental Fig.
S1A,B; Dimri et al. 1995). To unveil TIS-related changes
on the transcriptome level, we generated genome-wide
microarray gene expression profiles (GEPs) from 12
matched pairs of primary control;bcl2 lymphomas that
were either drug-senescent or untreated. Gene set enrich-
ment analysis (GSEA) demonstrated that NF-kB target
genes as a whole, and NF-kB-controlled cytokines in
particular, were strongly skewed toward the TIS group
(Fig. 1A; Supplemental Table 1). Supporting this result,
a multiplex DNA-binding ELISA-based analysis of
matched pairs of untreated versus senescent lymphomas
detected significantly higher DNA-binding activities for
the four NF-kB family subunits p50, p52, p65 (RelA), and
RelB in senescent cells, indicating that both the classical
and the alternative NF-kB pathways are activated in TIS
(Fig. 1B). Accordingly, immunofluorescence stained p65
in TIS lymphomas predominantly in the nucleus, while
nonsenescent cells displayed a preferentially cytoplasmic
localization (Fig. 1C). By immunoblot analysis, TIS lym-
phomas also presented with induced expression levels of
Ser 536-phosphorylated p65 (p65-P-S536), a post-trans-
lational modification considered to increase p65 trans-
activation function (Fig. 1D; Buss et al. 2004). To confirm
NF-kB activity at the level of individual target genes, we
measured the expression of transcripts that were among
the differentially regulated gene products in the micro-
array analysis by quantitative real-time PCR (RQ-PCR).
Indeed, all NF-kB target genes tested—non-secreted genes
and SASP in particular—were expressed at higher levels
in TIS compared with nonsenescent lymphoma cells (Fig.
1E). Taken together, activated NF-kB signaling is a prom-
inent feature of chemotherapy-related senescence in full-
blown tumor cells.
TIS depends on intact NF-kB function in vivo
Next, we asked whether TIS not only presents with
enhanced NF-kB activity, but also depends on it. First,
we tested whether inactivation of NF-kB by stable ex-
pression of the NF-kB superrepressor IkBa-DN (SR)—a
nondegradable IkBa moiety (Krappmann et al. 1996) pro-
ducing lowered expression levels of NF-kB target genes in
tumor necrosis factor-a (TNF-a)-treated and little impact
on proliferation in untreated lymphoma cells (Supplemen-
tal Fig. S2A,B)—is sufficient to interfere with functional
properties of the TIS condition. Indeed, the expression of
most NF-kB target genes—both SASP and nonsecreted
genes—was sharply reduced in the ADR-exposed SR-
engineered control;bcl2 lymphoma group, as further
highlighted in matched-pair analyses of the same indi-
vidual lymphomas with or without the SR moiety for
Jing et al.
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representative NF-kB-controlled SASP factors (Fig. 2A;
see Supplemental Fig. S2C for similar results obtained
upon exposure to a variety of pharmacological IKK in-
hibitors). Based on these findings, we addressed the
obvious question of whether ablation of NF-kB activity
would affect the inducibility of senescence following
chemotherapy. In fact, SA-b-gal-based analyses of
matched pairs differing only in their SR status revealed
a spectrum that reached from a substantial decline in the
percentage of SA-b-gal-positive cells in some to an
uncompromised TIS phenotype in other lymphomas of
the SR cohort, reflecting a mean reduction of SA-b-gal
reactivity by >30% and a corresponding average increase
of cell numbers by >2.5-fold in the SR compared with the
empty vector group (Fig. 2B; data not shown). Collec-
tively, these data suggest a modest contribution of
Figure 1. Enhanced NF-kB activity in ther-
apy-induced senescent primary lymphoma
cells. (A) GSEAs of NF-kB targets (left) and
the subset of cytokines and their modula-
tors therein (right) in the GEP of ADR
senescent versus untreated (ut) Em-myc
control;bcl2 lymphomas (n = 12 matched
pairs). (B) DNA-binding activity of the in-
dicated NF-kB subunits in lymphomas as in
A (n $ 3 matched pairs per subunit). (C)
Immunofluorescence of the NF-kB subunit
p65 in cytospin preparations of lymphoma
cells as in A (representative example of
three cases analyzed; bars, 50 mm). (D)
Immunoblot analyses of the indicated pro-
teins in cell lysates from four matched
lymphoma pairs as in A with H3K9me3 as
a senescence marker (Reimann et al. 2010)
and a-Tubulin as a loading control. (E) RQ-
PCR analyses of the indicated nonsecreted
(left) and secreted (right) transcripts in lym-
phomas as in A (n = 5 samples each). Shown
are relative expression levels, normalized
to an internal control, that are comparable
throughout all data sets. (Note the log-
scaled presentation in the cytokine panel.
All secreted NF-kB targets presented here
reflect SASP, while Igfbp7 is a SASP factor,
but not a bona fide NF-kB target.) All histo-
gram bars indicate mean values 6 standard
deviation (SDEV).
Figure 2. TIS is an NF-kB-dependent condition in
primary lymphomas. (A, top) RQ-PCR analyses of
the indicated transcripts in lymphomas presented as
the ratio of the relative values for ADR-exposed
versus untreated control;bcl2 lymphomas stably
expressing the NF-kB SR or being empty vector-
infected as a control (at least five samples each).
(Bottom) Matched ADR-exposed control;bcl2 lym-
phoma pairs 6 SR are shown for the relative
expression levels of two representative SASP fac-
tors. (B) Frequencies of SA-b-gal-positive cells from
matched lymphoma pairs 6 SR, exposed to ADR in
vitro (n = 7 pairs). (C) In situ frequencies of SA-b-gal-
positive as well as Ki67-positive cells in matched-
pair (6SR) lymphoma sections, exposed to CTX in
vivo (n = 3 pairs; representative photomicrographs
shown; bars, 100 mm). All histogram bars or num-
bers indicate mean values 6 SDEV.
NF-kB in treatment-induced senescence
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putative prosenescent NF-kB-governed functions in a
homotypic tumor cell population—irrespective of their
intracellular, autocrine, or paracrine modes of action
(Acosta et al. 2008; Kuilman et al. 2008)—at least in
a subset of genetically susceptible primary tumors.
Rather than functioning as a linear and essential compo-
nent of the DDR-initiated senescence pathway, it is very
well conceivable that the NF-kB network operates as
a corroborating, collateral relay of the prosenescent DDR.
In such a scenario, the uniform exposure of all cells to
a chemotherapeutic agent in culture would probably
launch such a strong DDR cascade in every given cell
that a quantitative reduction of a senescence-reinforcing
principle by the SR will not instantly translate into
a senescence-defective phenotype—except collateral pros-
enescent pathways became dysfunctional, therebymaking
the contribution of NF-kB signaling to TIS critical.
The in vivo situation is by far more complex, including
aspects such as inhomogeneous drug delivery and het-
erotypic cell–cell interactions that were not covered by in
vitro analyses. To address the potential contribution of
NF-kB activity to a drug-inducible senescence phenotype
in a scenario most closely recapitulating the natural
tumor situation, we decided to investigate genetically
compatible transplant lymphomas in vivo. Control;bcl2
lymphomas retrovirally infected with the SR construct or
an empty vector for comparison were transplanted into
normal, immunocompetent recipient mice, where they
formed systemic lymphomas indistinguishable from the
primary transgenic host they were initially derived from.
At the time a peripheral lymphadenopathy became pal-
pable, mice harboring a comparable tumor burden were
treated once with the DNA-damaging anti-cancer agent
cyclophosphamide (CTX), and lymphomas were analyzed
for in situ signs of TIS 5 d later. Intriguingly, TIS-competent
lymphomas presentedwith virtually no SA-b-gal reactivity
and >80% Ki67-positive cells following CTX exposure in
vivo if they expressed the SR moiety (Fig. 2C). Thus, SR-
expressing lymphomas displayed a much more profound
TIS defect in vivo, even if they exhibited only some
reduction of their SA-b-gal reactivity in vitro, indicating
a critical, NF-kB-dependent prosenescent contribution of
bystander cells within the tumor microenvironment. Of
note, senescence-associated interaction with host immune
cells is cocontrolled by NF-kB activity as well, as reported
by Lowe and colleagues (Chien et al. 2011; see also Xue
et al. 2007), thereby suggesting immune-mediated clear-
ance of senescent cells as another link by which NF-kB
may control tumor growth. Taken together, the NF-kB
network operates as a critical component of the drug-
inducible senescence response, whereby the actual quan-
titative impact of its interference with cell-autonomous
and non-cell-autonomous senescence-relevant processes
can only be appreciated in vivo.
Oncogenic networks determine opposing roles
of NF-kB on treatment outcome
Given the inability of SR-engineered Myc-lymphomas to
launch a TIS response in vivo, we aimed to quantify and
dissect the contribution of NF-kB signaling to the long-
term outcome of naturally formed B-cell lymphomas
prior to any therapy. While mouse models of cancer
harboring defined genetic lesions in candidate pathways
are important research tools, they may miss or even
disturb critical oncogenic network interactions that drive
naturally developing tumors. Therefore, we started from
a series of 12 primary Em-myc lymphomas, assessed their
endogenous NF-kB activation level by p65 DNA-binding
ELISA, and grouped them accordingly as an ‘‘NF-kB low’’
(NL, the four lowest cases) and an ‘‘NF-kB high’’ (NH, the
four highest cases) cohort (Fig. 3A). First, we sought to
determine their short-term drug sensitivity, reflecting
their apoptotic potential. Expectedly, the NH group was
Figure 3. Em-myc lymphomas driven by high en-
dogenous NF-kB levels display NF-kB/Bcl2-mediated
chemoresistance. (A) Stratification of 12 primary
control lymphomas in an ‘‘NF-kB low’’ (NL; black
bars), an intermediate (gray bars), and an ‘‘NF-kB
high’’ (NH; white bars) group according to their NF-
kB p65 DNA-binding activities at diagnosis (mea-
sured in triplicate; horizontal lines indicate mean
activity within the respective groups). (B) Viability
analysis by trypan blue dye exclusion of the NL
versus NH lymphoma cell populations exposed in
vitro for 24 h to 5 ng/mL ADR relative to untreated
cells of the same group (n = 4 each group). (C) RQ-PCR
analyses of the transcript levels of the NF-kB target
bcl2 in the lymphoma groups as in B. (D) Viability
analysis as in B and with the same lymphoma sam-
ples, now overexpressing Bcl2 from retroviral alleles
in both groups. (E) GFP enrichment analysis of MSCV-
SR-IRES-GFP-expressing cells treated as in B, but for
48 h; selective drop of GFP-positive cells in the NH
group indicating their increased chemosensitivity
upon NF-kB inhibition (n = 3 each group). All histo-
gram bars indicate mean values 6 SDEV.
Jing et al.
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virtually resistant to ADR treatment in vitro, while
lymphoma cells of the NL group quantitatively died at
the same dose level (Fig. 3B). Since Bcl2 is frequently
detected at overexpressed levels in human B-cell lym-
phomas and a bona fide NF-kB target, we reasoned that
chemoresistance might be mediated in NH lymphomas,
at least in part, via induction of Bcl2 (Schmitt et al. 2000;
Feuerhake et al. 2005). Indeed, Bcl2 transcript levels,
measured by RQ-PCR, were significantly higher in the
NH compared with the NL group (Fig. 3C). When we
overexpressed Bcl2 from retroviral alleles in both groups,
Bcl2 rendered NL lymphomas as chemoresistant as NH
lymphomas (Fig. 3D). Conversely, we asked whether in-
hibition of NF-kB activity might overcome the short-term
drug resistance in the NH group. While inactivation of NF-
kB function by the SR moiety had little impact in the NL
group, it restored chemosensitivity in the NH group,
thereby uncovering highly active NF-kB signaling as an
‘‘Achilles’ heel’’ of this group during chemotherapy (Fig. 3E;
Staudt 2010). Taken together, a proportion of primaryMyc-
driven lymphomas presents with high-level NF-kB activity
at diagnosis, suggestive for an oncogenic function of the
NF-kB network selected for during lymphoma development
that simultaneously anticipates primary drug resistance.
Recapitulating the clinical outcome of patients suffering
fromDLBCL,;60% of themice harboring Em-myc control
lymphomas achieve long-term remissions (reflecting cure),
while the remaining 40% encounter a relapse after CTX
induction therapy (Schmitt et al. 1999, 2000; Lenz et al.
2008b).We generated ‘‘time-to-relapse’’ data for 13 primary
(not bcl2-infected) Em-myc lymphomas transplanted into
recipient mice and exposed to CTX at the time of
lymphoma manifestation. While all animals entered a re-
mission, seven lymphomas relapsed within the 100-d ob-
servation period, allowing us to group the 13 lymphomas
at diagnosis as either ‘‘never relapse’’ (NR) or ‘‘relapse-
prone’’ (RP). Based on the previous results, we assessed
basal NF-kB activity by the expression of IkBa, a central
NF-kB regulator and NF-kB target, as well as Bcl2 in
untreated lymphomas of these two groups (Fig. 4A).
Strikingly, RP lymphomas were found to exhibit signifi-
cantly higher IkBa expression levels, further accompanied
by substantially higher bcl2 expression levels, thus remi-
niscent of the NF-kB/Bcl2 network analyzed in Figure 3
and of the genetic hallmark lesions detectable in acti-
vated B-cell-like (ABC) DLBCL, the prognostically in-
ferior DLBCL subtype characterized by constitutively
active NF-kB signaling due to a variety of activating
mutations in the NF-kB pathway and by very high Bcl2
transcript levels (Iqbal et al. 2006; Lenz et al. 2008b;
Compagno et al. 2009; Staudt 2010; Nogai et al. 2011).
In contrast, germinal center B-cell-like (GCB) DLBCL
present with a much better clinical outcome (Lenz et al.
2008b), although Bcl2 overexpression is common in this
subtype as well. Importantly, GCB DLBCL rarely possess
activating NF-kB mutations, but frequently (;45%) de-
velop in the context of a t(14;18) translocation that drives
Bcl2 overexpression via the immunoglobulin heavy chain
locus in an NF-kB-independent fashion, a lesion that is
virtually never found in ABC-type DLBCL (Nogai et al.
2011). If drug-inducible apoptosis is blocked in mouse
lymphomas by exogenous Bcl2 overexpression, thereby
mimicking the GCB-related t(14;18) translocation, NR
lymphomas were able to enter TIS (data not shown). To
test whether higher NF-kB activation levels would fur-
ther promote senescence induction in these lymphomas,
we made use of a strongly NF-kB-activating CARD11
(also known as CARMA1 or Bimp3) mutant, the murine
homolog of the human CARD11-L244P mutant, whose
overexpression results in increased NF-kB target gene
Figure 4. Differential oncogenic wiring deter-
mines opposing roles of NF-kB in treatment out-
come. (A) Grouping of 13 primary control lymphomas
according to the long-term responses to CTX
therapy following transplant tumor formation in
vivo as either ‘‘never relapse’’ (NR) or ‘‘relapse-
prone’’ (RP) lymphomas, and RQ-PCR analyses of
their IkBa transcript levels at diagnosis (i.e., prior
to any therapy) as a representative bona fide NF-
kB target (left) and of Bcl2 levels of the same
samples (right; presented in the same order);
horizontal lines indicate mean activity within
the respective groups. (B) Frequencies of SA-
b-gal-positive cells in Bcl2-overexpressing NL
lymphomas 6 CARD11-L251P, exposed for 3
d to 50 ng/mL ADR in vitro (n = 4 matched pairs;
representative photomicrographs of cytospin
preparations are shown below the corresponding
bars). (C) Progression-free survival of the 49 R-
CHOP-like-treated GCB DLBCL patients from
a total of 233 patients (as reported by Lenz et al.
2008b) with an above-median Bcl2 expression by
microarray-based transcriptome analysis of their
lymphomas at diagnosis, and further stratified by a 63-gene signature as either ‘‘NF-kB high’’ (NH, n = 25; green) or ‘‘NF-kB low’’
(NL, n = 24; blue). All histogram bars indicate mean values 6 SDEV.
NF-kB in treatment-induced senescence
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expression (Supplemental Fig. S3; Lenz et al. 2008a). While
naturally occurring CARD11 mutations are preferentially
found in ABC DLBCL, we here used such a mutant to
enhanceNF-kB activity in a ‘‘GCB-reminiscent’’ lymphoma
cohort, which formed in the absence of highly activated
NF-kB andwhere apoptosis is blocked independently ofNF-
kB via autochthonous Bcl2 overexpression. Indeed, at an
early time, when ADR-exposed Bcl2-engineered NL lym-
phomas were still largely negative for signs of TIS, a high
proportion of the matching, mutant CARD11-overexpress-
ing lymphoma cells already stained positive for SA-b-gal
activity (Fig. 4B), suggesting that higher NF-kB activity
contributes to treatment outcome via TIS promotion.
Therefore, we decided to interrogate a large data set of
DLBCL GEP and clinical data after rituximab-CHOP-like
standard immunochemotherapy (which includes both
ADR and CTX) from 233 patients (Lenz et al. 2008b),
and asked in the subset of GCBDLBCL patients with high
Bcl2 expression whether a previously identified NF-kB
gene expression signature consisting of 63 known NF-kB
target genes would allow us to stratify two patient
cohorts with different clinical outcomes (Shaffer et al.
2006). Indeed, as shown in Figure 4C, Bcl2-overexpressing
GCBDLBCL patients with anNF-kB signature expression
above median (NH; n = 25) had a significantly superior
progression-free survival when compared with the com-
plementary NL group (n = 24; P < 0.005), while such
a correlation was not found in patients harboring high
Bcl2-expressing lymphomas of the ABC subtype or lym-
phomas of either subtype with low Bcl2 expression
(Supplemental Fig. S4; data not shown). Notably, multi-
variate analysis indicated that the NF-kB status in Bcl2-
overexpressing GCB DLBCL cases is statistically indepen-
dent of the International Prognostic Index overall score
(P = 0.3956), which is used as a clinical standard to predict
outcome in lymphoma patients (The International Non-
Hodgkin’s Lymphoma Prognostic Factors Project 1993).
Taken together, our experimental strategy led to the iden-
tification of a genetically defined and clinically signifi-
cant subgroup of GCB DLBCL patients who experienced
superior treatment outcome if NF-kB signaling was hy-
peractive, thereby contrasting the well-established asso-
ciation of the ABC subtype with constitutively active
NF-kB signaling and poor treatment outcome.
Discussion
Cellular senescence not only acts as a tumor-suppres-
sive principle, but contributes to the outcome of cancer
therapy in vivo (Schmitt et al. 2002; Haugstetter et al.
2010). ActivatedNF-kB signaling hasmostly been linked to
treatment resistance, especially when measured as inabil-
ity to enter drug-induced apoptosis in short-term assays
(Wang et al. 1999). As suggested by previous studies linking
OIS to the massive production of a large variety of
cytokines of which many possess NF-kB-binding sites in
their promoters, we report here a dramatic induction of
nonsecreted and secreted NF-kB target genes during TIS
and, importantly, a dependency of the senescent phenotype
on functional NF-kB signaling that becomes particularly
evident in vivo—a finding in full agreement with related
work by Lowe and colleagues in this issue (Chien et al.
2011). While enforced NF-kB activation due to mutant
Card11 expression accelerated TIS in vitro, themuchmore
pronounced impairment of TIS following NF-kB inhibition
in vivo as compared with the in vitro situation indicates
additional, non-cell-autonomous implications of NF-kB
signaling in the senescence process. Our observation of
a virtual absence of senescence in NF-kB-defective lym-
phoma cells at a time when NF-kB-competent lymphomas
became largely senescent argues for prosenescent factors
released by adjacent cells in response to NF-kB-dependent
signals originating from the treated tumor cells, reminis-
cent of the non-cell-autonomous mode of senescence
induction recently reported for macrophages during Em-
myc lymphomagenesis (Reimann et al. 2010).
Although our results demonstrate an essential role for
NF-kB in the induction of cellular senescence in a genet-
ically defined model scenario, the overall impact of NF-
kB activity levels on treatment outcome in natural
tumors ismuchmore difficult to assess. Our cross-species
investigation strategy was instrumental in unveiling
a genetically defined tumor subset with a distinct NF-
kB-dependent responsiveness. Based on human DLBCL
data linking the ABC subtype to activating NF-kB lesions
and an inferior outcome to standard immunochemother-
apy (Lenz et al. 2008b; Compagno et al. 2009), we first
classified a series of primary Em-myc transgenic lympho-
mas with known long-term responses to chemotherapy in
vivo based on their NF-kB activity levels at manifesta-
tion. Reminiscent of GCB-type DLBCL, the group of Em-
myc lymphomas with good clinical outcome was largely
composed of lymphomas exhibiting low basal NF-kB
activity. These mouse lymphomas were subsequently
used to experimentally explore the contribution of en-
hanced NF-kB activity to senescence induction after
drug-inducible apoptosis was independently blocked by
retroviral Bcl2 overexpression. Ultimately, we used the
genetic determinants of this TIS-prone scenario—GCB-
reminiscent lymphomas with high Bcl2 expression and
high NF-kB activity—to interrogate a large GEP set
derived from 233 DLBCL patients with known clinical
outcome to therapy. Strikingly, we were able to confirm
the mechanistic results from the murine lymphoma
model in DLBCL-harboring patients. The ‘‘Bcl2 high/
NF-kB high’’ GCBDLBCL subgroup of patients presenting
with a significantly prolonged survival after therapy un-
derscores a hitherto unknown beneficial association of
NF-kB hyperactivation and treatment outcome in lym-
phoma patients and would not have been identified
without the cross-species investigation of primary Em-
myc lymphomas. Our approach illustrates the power of
mouse models to recapitulate defined genetic determi-
nants of human tumor cohorts, followed by the genetic
manipulation and subsequent functional exploration of
murine surrogate tumors with the ultimate goal to use
mouse-derivedmechanistic information for a reassessment
of the human data set to gain novel functional insights.
Our data highlight how oncogenic networks and in-
terdependencies, wired up during tumor development,
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may regulate the actual functions and even opposing
roles of NF-kB in subsequent responses to therapy. NF-
kB mutations acquired during lymphoma development,
as preferentially observed in the ABC subtype of DLBCL,
account for the selective vulnerability of these lympho-
mas to NF-kB inhibitors or shRNAs targeting compo-
nents of the NF-kB pathway (Davis et al. 2001; Ngo et al.
2006). Since the anti-apoptotic bcl2 gene is a bona fide
NF-kB target, ABCDLBCLs are genetically determined to
depend on an NF-kB/Bcl2 signaling module, while GCB
DLBCLs frequently present with bcl2 translocations that
uncouple their anti-apoptotic activity from NF-kB up-
stream control. Unlike tumors characterized by a broad
spectrum of detrimental biological properties directly
linked to their constitutively active NF-kB network,
tumor types that do not rely on NF-kB signaling as the
driving oncogenic force but present with an NF-kB-in-
dependent apoptotic block may use the prosenescent
potential of NF-kB signaling to execute TIS as an alter-
native, outcome-improving chemotherapeutic effector
mechanism. Our mouse model findings obtained in
Myc-driven lymphomas engineered to overexpress Bcl2
not only genetically approximate the human Myc/Bcl2
‘‘double-hit’’ lymphomas most frequently found in the
GCB subtype of DLBCL, but also more advanced follicu-
lar lymphomas, which, in addition to their t(14;18)
hallmark lesion, often acquire activating Myc lesions in
the course of the disease, and, of note, also do not belong
to NF-kB-hyperactivated lymphoma entities (Aukema
et al. 2011). AlthoughNF-kB’s role in cancer development
and therapy is very complex, our mouse model– and
patient-derived data suggest that we should carefully
select, or at least monitor, genetically defined patient
subcohorts in which therapeutic interference with the
NF-kB pathway may or may not be of clinical benefit
(Dunleavy et al. 2009; Ruan et al. 2011).
Materials and methods
Mice, lymphoma monitoring, and in vivo treatment
All animal protocols used in this study were approved by the
governmental review board (Landesamt Berlin) and conform to
the respective regulatory standards. Em-myc transgenic mice were
genotyped by allele-specific genomic PCR and monitored for
lymphoma onset (Adams et al. 1985; Schmitt et al. 1999). Viable
lymphoma cells were isolated, transplanted by tail vein injection
into strain-matched C57BL/6 recipient mice (;33 106 to 5 3 106
cells per mouse), or propagated in culture, and preservation of
snap-frozen or formalin-fixed lymph node tissue was carried out
as described (Schmitt et al. 1999). At the moment lymph nodes
became palpable in recipient animals, mice were exposed to
a single intraperitoneal dose of CTX (300 mg/kg body weight),
and responses were monitored by lymph node palpation or in
lymphoma material isolated at day 5 after therapy (Schmitt et al.
1999, 2002).
Site-directed mutagenesis, plasmids, and retroviral
gene transfer
The oncogenic CARD11-L251P mutation (the murine homolog
of the human CARD11-L244P mutation detected in the ABC
DLBCL cell line OCL-Ly3) (Lenz et al. 2008a) was generated by
site-directed mutagenesis of full-length wild-type murine
CARD11 (BioCat). cDNAs encoding murine wild-type CARD11,
CARD11-L251P, Bcl2, and the NF-kB SR (Krappmann et al. 1996)
were subcloned into the murine stem cell retrovirus (MSCV; i.e.,
into MSCV-IRES-GFP or MSCV backbones coexpressing a blasti-
cidin or puromycin antibiotic resistance gene). Retroviral super-
natants, generated by transient transfections of Phoenix packag-
ing cells with the respectiveMSCV plasmids, were used to stably
infect Em-myc transgenic lymphoma cells as described (Schmitt
et al. 2000).
Growth parameters and in vitro drug assays
Cell numbers and cellular viability were assessed by trypan blue
dye exclusion, and cytotoxicity or cellular senescence was
measured 24 h or 5 d, respectively, after the addition of ADR at
the indicated concentrations (Schmitt et al. 1999; Reimann et al.
2010). In some experiments, lymphoma cells were pre-exposed
for 30 min to the pharmacological NF-kB inhibitors Bay11-7082
(1 mM; an IkBa phosphorylation inhibitor; Sigma-Aldrich),
TPCA-1 (0.5 mM; an IKK-2 inhibitor; Merck), or KINK-1 (0.4
mM; an IKK-2 inhibitor; kindly provided byM. Schmidt-Supprian
[Schon et al. 2008]) prior to a subsequent ADR treatment, or were
treated with TNF-a (Sigma-Aldrich) at 50 mM for 30 min or 24 h.
For GFP enrichment analyses of MSCV-SR-IRES-GFP-infected
cells, changes in the percentage of GFP-positive cells prior to and
after ADR exposure were normalized by the respective fractions
of GFP-positive cells infected with anMSCV-GFP control vector.
Cytospin preparations of suspension cultures for subsequent
antigen- or SA-b-gal activity-detecting staining as well as in
situ-SA-b-gal analyses in cryosections of snap-frozen lymph
nodes were carried out as previously described (Schmitt et al.
2002; Braig et al. 2005; Reimann et al. 2010).
NF-kB DNA-binding activity
DNA-binding activity of the five mammalian NF-kB subunits
was measured using the TransAm Flexi NFkB Family transcrip-
tion factor ELISA assay (Active Motif) in accordance with the
manufacturer’s protocol.
Gene expression analyses
For RQ-PCR analyses of NF-kB target genes in lymphoma cells,
RNA extracted with TRIzol (Invitrogen) was transcribed into
cDNA using SuperScript reverse transcriptase (Invitrogen) and
random hexamers or oligo-dT. RQ-PCR analyses of murine Bcl2,
CCL2, CCR7, c-FLIP, CXCL1, CXCR2, Cyclin D2, GADD45b,
GAPDH, GM-CSF, IGFBP6, IGFBP7, IkBa, IL-1a, IL-6, IRF-4,
and SOD2 transcripts were conducted based on commercially
available primers (Applied Biosystems). For every given sample,
DCt values were determined as the difference between the Ct
value of a specific transcript and the Ct value ofGAPDH, serving
as the housekeeping control mRNA, and relative transcript
levels (e.g., treated vs. untreated) were then produced based on
2(DDCt) with DDCt = DCttreated  DCtuntreated.
Immunoblotting was carried out using whole-cell lysates,
generated by lysing cells in sodium dodecyl sulfate (SDS) sample
buffer (60 mMTris-HCl at pH 6.8, 10% glycerol, 2% SDS, and 5%
2-mercaptoethanol), resolved on a 12% SDS-PAGE, and trans-
ferred to an Immobilon-P membrane (Millipore) using antibodies
against Bcl2 (1:2000 dilution; #554087, BD Pharmingen) (data not
shown), H3K9me3 (1:1000; ab8898, Abcam), NF-kB p65 (1:1000;
#3034, Cell Signaling Technology), NF-kB p65-P-S536 (1:1000;
#3033, Cell Signaling Technology), and a-Tubulin (1:2500;
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T5168, Sigma) as a loading control (Schmitt et al. 1999). For
immunofluorescence, cells were fixed in 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100/PBS, blocked in 1%
bovine serum albumin, and incubated with a primary antibody
against p65 (1:250; Santa Cruz Biotechnologies, SC-372), fol-
lowed by 0.01% Tween 20 as detergent buffer and the secondary
anti-rabbit IgG antibody (1:400; AlexaFluor 488 [A11008], Invi-
trogen); slides were stained with DAPI (49,6-diamidino-2-phenyl-
indole) as a nuclear counterstain and mounted with Mowiol 4-88
(Calbiochem). For immunostaining of Ki67, 2% paraformalde-
hyde-fixed cytospin preparations or tissue cryosections were in-
cubated with the primary antibody against Ki67 (1:25; M7240,
Dako), followed by a streptavidin–biotin complex peroxidase kit
(LSAB+ System-AP, DakoCytomation), used according to the
manufacturer’s instructions.
For microarray-based gene expression profiling, RNA was
isolated from untreated or 5-d ADR-treated control;bcl2 Em-
myc lymphomas using the RNeasy minikit (Qiagen) and hybrid-
ized to Affymetrix Mouse Genome 430 2.0 microarrays (Affyme-
trix) according to the manufacturer’s instructions. The arrays
were hybridized and washed in the GeneChip Fluidics Station
450, and signals were detected on an Affymetrix GeneChip
Scanner 3000. Affymetrix files were imported into Partek
Genomic Suite software (version 6.4, Partek, Inc.) and processed
by the implemented robust multiarray (RMA) work flow (con-
sisting of median polish probe set summarization, RMA back-
ground correction, and quantile normalization). The raw micro-
array data were deposited at the Gene Expression Omnibus
(GEO) repository of the National Center for Biotechnology
Information under the accession number GSE31099 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31099).
For further analysis of mouse microarray data, genetic signa-
tures of NF-kB activation were taken without further change
from the Thomas Gilmore laboratoryWeb site (a complete list of
genes and related references is available at http://www.bu.edu/
nf-kb/gene-resources/target-genes). The enrichment of NF-kB
target gene sets within the global transcript signals from
matched pairs of untreated versus ADR-treated control;bcl2
lymphoma cells was analyzed by applying the GSEA version
2.0 software (Broad Institute of the Massachusetts Institute of
Technology and Harvard, http://www.broad.mit.edu/gsea). Nor-
malized enrichment scores (NES) reflect a statistically signifi-
cant enrichment for P-values <0.05 and FDR (false discovery rate)
values <0.25 (Subramanian et al. 2005).
Gene expression data of lymphoma biopsies from 233 pa-
tients, who were treated with R-CHOP-like immunochemother-
apy and profiled using Affymetrix HG-U133 Plus 2.0 microarrays
(Lenz et al. 2008b), were obtained from the NCBI GEO
(GSE10846). Patients were classified into ABC DLBCL, GCB
DLBCL, and unclassified DLBCL according to Lenz et al. (2008b).
The 100 GCB DLBCL patient samples, for which clinical follow-
up information for progression-free survival was available, were
equally divided into groups of high and low Bcl2 expression, based
on the median expression. Within these two cohorts, patients
were subsequently divided into high and low NF-kB groups ac-
cording to the median expression of a previously described NF-kB
gene expression signature consisting of 63 known NF-kB target
genes (http://lymphochip.nih.gov/cgi-bin/signaturedb/signatureDB_
DisplayGenes.cgi?signatureID=83; Shaffer et al. 2006).
Statistical evaluation
The survival of GEP-related patient subcohorts was calculated
using Kaplan-Meier estimation and compared with the log-rank
(Mantel-Cox) test. Pearson’s x2-test was applied in multivariate
analysis. The unpaired t-test was used to compare means and
standard deviations. All quantifications from staining reactions
(i.e., immunostainings or SA-b-gal assays) were carried out by an
independent and blinded second examiner and reflect at least
three samples with at least 200 events counted (typically inmore
than three different areas) each. A P-value <0.05 was considered
statistically significant and was marked by an asterisk.
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